Fundraising FoxKurma Partners — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.
BiotechMedical DevicesZurich, CH
Co-investorsPureos BioventuresYsios CapitalAdjuvant CapitalFresenius Medical Care VenturesVerve Venturesredalpine
.jpeg){kind=logo}
Raidium builds an AI-native PACS viewer embedding a vision-language foundation model to support radiologists across research and clinical work, including automated tumor measurement and lesion segmentation.
AI & Machine LearningDigital HealthMedical DevicesParis, FR
Paul Herent, M.D., Msc(Founder)inPaul Hérent(Founder)inPierre Manceron(Founder)inSebastian Schwarz(COO)inDamien Benard(CFO)in
Co-investorsFounders FutureGalion.exeNewfund CapitalDebiopharm Innovation FundStartX
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsDroia VenturesPureos BioventuresEQT Life SciencesSeroba Life SciencesEurazeoIdinvest Partners+1 more
Spotlight Medical develops AI-enabled prognostic assays for cancer risk assessment, starting with myStage Dx, a test for early-stage ER+/HER2– breast cancer that helps clinicians identify low-risk patients within high-risk clinical groups.
AI & Machine LearningDigital HealthMedical Devices
Sylvain Berlemont(Cofounder & Chief Executive Officer)inMarvin Lerousseau(Cofounder & Chief Scientific Officer)in
Co-investorsHeal Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.